Currently, recombinant human EPO (rHuEPO) is the approved treatment for patients with anemia due to CKD. Despite the success of rHuEPO as a therapy for anemia in CKD, various adverse effects have been reported (Frank et al., 2004; Goldberg et al., 1992) . For example, patients can become EPO resistant and also hyporesponsive to the biologic (van der Putten et al., 2008) . Furthermore, observations in a clinical trial with patients that suffer from anemia due to chemotherapy indicated that rHuEPO increases lethality in these patients (Bohlius et al., 2009) . Results of another large clinical trial on patients with anemia and either diabetes or CKD determined that rHuEPO therapy did not reduce the risk of death due to either cardiovascular or renal complications in these patients (Pfeffer et al., 2009 ). The trial also indicated that rHuEPO therapy could lead to an increased risk of stroke in these patients. However, because rHuEPO rapidly raises the patient's hemoglobin level, it is possible that the observed detrimental effects of rHuEPO therapy are attributable to the sharply increased levels of hemoglobin rather than being an effect of the drug itself (e.g. crossreactivity to other targets). Nevertheless, on the basis of these observations it is now recommended that the patient's hemoglobin level should not exceed 12 g/dl. Taken together, the development of erythropoiesis-stimulating agents (ESAs) that function without activating the EPOR complex would offer valuable alternative treatment options (Bunn, 2007; Wrighton et al., 1996) .
At present, few in vivo models exist that display a phenotype similar to the anemia of CKD: specifically, low RBC production in conjunction with depleted sEPO levels. Models involving chemical injections are used to directly destroy RBCs and lower RBC indices. For instance, the injection of phenylhydrazine (PHZ) results in the destruction of RBCs by binding to hemoglobin proteins within these cells (Augusto et al., 1982) . The massive loss of RBCs causes the animal to undergo a stress-induced erythropoietic response but can also bring about deleterious secondary affects, e.g. liver damage (Jonen et al., 1982) . Alternatively, oxygen levels can be reduced in hyperbaric chambers, resulting in low tissue oxygenation in the animal. However, regardless of the methods employed, these current techniques lead to a rapid increase in sEPO levels and are not representative of an EPO-deficiency anemia. To overcome this caveat, nephrectomy has been used to create an EPO-limiting environment in vivo. However, this model involves an invasive procedure and is therefore not appropriate for large-scale experiments such as screening of preclinical compounds. In addition, these animals experience a shortened lifespan, which prevents the study of long-term effects of low EPO production. Finally, nephrectomized animals are still able to produce EPO in secondary tissues such as the liver (Tan et al., 1991) .
The introduction of transgenic mice technology has also yielded some innovative mouse models for the study of EPO function; however, these are not without caveats. For example, Epo-knockout mice are embryonic lethal, making it an ineffective model to study anemia and erythropoiesis in the adult system (Wu et al., 1995) . The authors determined that EPO was not necessary for erythroidlineage commitment; rather, it facilitated the survival of erythroid progenitors (CFU-E) that could then differentiate into RBCs. In another model, Maxwell and colleagues established a transgenic mouse in which the SV40-TAg sequence was inserted into the 5Ј sequence of the Epo gene. This gene modification leads to a dramatic decrease in Epo expression and consequently the animals display a severe chronic anemia (Maxwell et al., 1993) . However, the EPO-TAg mice also develop an immune response to EPO that is probably due to a sensitizing effect of the expressed SV40 T antigen (Rinsch et al., 2002) .
To facilitate the creation of a new model for the anemia of EPO deficiency, we developed a conditional Epo-knockout mouse by inserting loxP sites into the Epo gene (Claxton et al., 2008; Li et al., 2006) . By crossing this floxed Epo allele to an inducible Cre transgene (Rosa26-CreER
T2
) Epo was postnatally ablated (Seibler et al., 2003) . After induction of Cre activity, Epo expression and sEPO levels were substantially reduced. Accordingly, these conditional-knockout mice experienced a significant reduction in RBCs, although mean corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV) remained normal. In addition, an analysis of the bone marrow progenitors of Epo-knockout animals showed no effect on the erythroid progenitors BFU-E and CFU-E. Therefore, these mice develop a chronic, normocytic and normochromic anemia in conjunction with low sEPO levels that correlate to the clinical display of patients with anemia due to CKD. However, in contrast to patients with CKD, these animals do not develop inflammation or uremia and therefore will allow the study of erythropoiesis in an EPO-limiting environment without the bias of possible secondary complications. Taken together, these results demonstrate that this mouse model can serve as a preclinical tool to study chronic anemia due to EPO deficiency.
RESULTS

Conditional deletion of Epo leads to a reduction in Epo mRNA and sEPO levels
We analyzed the impact of Epo deletion in adult mice by employing a conditional-knockout strategy (Claxton et al., 2008; Seibler et al., 2003) . To induce Epo deletion, mice in which exon 2 through 4 was flanked by loxP sites were generated (Fig. 1A,B) . These exons encode for the amino acid sequences necessary for EPOR binding. After obtaining germline transmission, Epo WT/flox mice were crossed with each other to obtain homozygous Epo flox/flox mice. These mice seemed phenotypically normal to their wild-type counterparts (data not shown). Epo flox/flox animals were bred to the EIIa-Cre mice, which ubiquitously express Cre, to generate Epo / embryos. These embryos died at 12.5 days post-coitum (dpc) with severe defects in erythropoiesis (Fig. 1C ). An absence of definitive RBCs in the Epo / embryos was observed in the fetal liver;
however, erythroid precursors were present in the yolk sac of these animals, as verified by CD71 + /Ter119 + staining (data not shown). Thus, the phenotype of Epo / embryos is similar to previously described Epo-knockout mice (Suzuki et al., 2002; Wu et al., 1995 animals. Also, sEPO levels were monitored during the acute hypoxic event. In this respect, it is worth noting that homeostatic levels of sEPO are undetectable with current technologies owing to the low protein concentration in normal mouse serum. Therefore, sEPO levels were also monitored in mice undergoing a stress-induced erythropoietic response due to PHZ treatment. In agreement with the Epo mRNA data, sEPO levels in Epo / mice were approximately 10% of those of Epo WT/ mice after PHZ treatment (data not shown and see below). These results indicate that induction of Cre activity leads to a severe ablation of Epo mRNA as well as a reduction in sEPO levels. qRT-PCR analysis was next performed on a gene known to be directly regulated by EPO signaling, Bcl2l1. In agreement with the Epo mRNA and sEPO data, we observed a significant reduction of Bcl2l1 expression in the bone marrow (Fig. 1E) . Taken together, these data demonstrate that the induced deletion of the Epo gene results in a decrease in sEPO levels, which in turn leads to decreased EPO signaling in the bone marrow. (Fig. 2B ).
Complete blood count (CBC) indices partially rebounded and stabilized after the first 30 days, although their HCT levels were still 25% below pre-induction levels. This observation suggested that tamoxifen might have a deleterious effect on erythropoiesis.
To evaluate whether tamoxifen caused adverse effects, tamoxifen
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Preclinical model for anemia of CKD RESEARCH ARTICLE Table 2 ). However, another explanation for the observed mild rebound could be that the activated CRE-ERT2 protein produces some toxic effects. It is known that the CRE protein is not well tolerated by cells and high levels of CRE can lead to cell death. In this respect it is curious to note that the HCT values slightly rebounded after removal of the inducer. Taken together, it seems that the induction of CRE-ERT2 by tamoxifen affects erythropoiesis. For this reason, all subsequent studies were performed with animals that were at least 50 days postinduction.
Between These findings are in corroboration with previously described observations in Epo-knockout mice (Jelkmann, 2007; Wang and Semenza, 1993) . Taken together, these data show that the Epo conditional deletion led to the development of a chronic, normocytic and normochromic anemia.
Loss of Epo leads to a decrease in mature erythroid cells in the bone marrow Epo
, Epo WT/ and Epo WT/WT bone marrow and spleen cells were tested for their potential to differentiate into committed erythroid progenitors. The number of progenitor colonies in bone marrow and spleen were statistically similar in Epo / , Epo WT/ and Epo WT/WT mice (Fig. 3 ). This observation is comparable to the previously described Epo-knockout mice (Wu et al., 1995) . Also, no differences in either size nor morphology were detected within the BFU-E and CFU-E colonies of Epo
cells. To further evaluate the erythron, bone marrow and spleen erythroid precursors were analyzed using CD71 and Ter119 markers (Zhang et al., 2003 erythroid stage (Fig. 4) were similar (68 pg/ml vs 76 pg/ml, respectively; Fig. 5A ). Mice were treated with PHZ to induce an acute hypoxic response and were monitored for 14 days. Epo WT/ and Epo / animals showed no differences in the rate of recovery from the acute anemia, as monitored by their rise in HCT levels (Fig. 5A ). As expected, Epo WT/ mice showed a substantial increase in sEPO levels compared with Epo / mice. At 2 days after PHZ injection, sEPO levels were more than tenfold higher in EPO WT/ mice compared with the Epo / animals (1000-10,000 pg/ml vs 100-800 pg/ml, respectively). Furthermore, no difference in spleen size was observed between Epo WT/ and Epo / mice, indicating that extramedullary erythropoiesis was normal in these animals. FACS analysis revealed no significant differences in erythroid progenitor populations in either bone marrow or spleen during recovery (Fig.  5B ). These data suggest that, although EPO production is severely diminished in Epo / mice, the erythropoietic system is fully capable to respond to an acute hypoxic event.
Epo / mice display low EPO levels in correlation with low HCT levels, similar to CKD patients Finally, HCT values were compared with sEPO levels in Epo
Epo
WT/ and Epo WT/WT transgenic mice (Fig. 6 ). The inverse relationship between sEPO levels and HCT values has been observed and is characterized by low HCT values in correlation with significantly increased sEPO levels (Artunc and Risler, 2007) . As shown in Fig. 6 , this relationship was observed in Epo WT/WT mice, whereas heterozygous animals (Epo WT/ ) displayed lower sEPO level compared with HCT levels. In addition, Epo / mice showed a dramatic reduction of sEPO in relation to low HCT levels. For example, Epo / mice with an HCT of 20% displayed an sEPO level of 100-300 pg/ml. In sharp contrast to this, Epo WT/WT animals with an HCT of 30% were able to produce sEPO levels well above 10,000 pg/ml.
DISCUSSION
In this study, we describe the generation and characterization of a mouse model for the anemia of CKD. To create this model, an inducible Cre-loxP system was used that allowed for the deletion of Epo in the adult animal. After induction of Cre, the level of sEPO significantly decreased and the animals developed a moderate anemia with normal MCV and MCH indices. However, the reduction in sEPO levels did not affect early erythroid progenitors in the bone marrow, as demonstrated by CFU-C assays and FACS analysis. These results are in agreement with previously published data of EPO-deficient animals (Wu et al., 1995) .
Some variations in the model characterized here versus previously generated Epo-knockout mice were observed. For instance, animals heterozygous for the Epo gene (Epo WT/ and Epo /flox ) consistently displayed a reduced HCT level compared with Epo WT/WT animals. Furthermore, the amount of late-stage erythroid precursors in the bone marrow (CD71 Neg /Ter119 + cells) was reduced in a dose-dependant manner. This decrease could be the result of an early egress of reticulocytes. It has been shown that under hypoxic conditions sinusoid pores in the bone marrow widen and release reticulocytes (Stohlman et al., 1954) . In agreement with this, a minor increase in peripheral blood reticulocytes of Epo / animals was observed. These differences could be the result of the Epo  locus design. The model described here was created by inserting loxP sites into the Epo allele. Although this insertion should not affect the expression of the Epo gene, it is possible that the integration influenced expression levels. We did not, however, find any known enhancer sequences within the region of loxP integration. Nevertheless, the significantly lower HCT in the Epo /flox Cre Neg mice compared with Epo WT/ animals indicates that the insertion of the loxP sites decreased Epo expression levels. Finally, a potential deleterious effect of the Cre-recombinase protein on erythropoiesis can be ruled out because Epo WT/flox mice
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Preclinical model for anemia of CKD RESEARCH ARTICLE that carry no Cre allele show the same decrease in HCT as the Epo WT/flox mice after induction of Cre activity, thus becoming Epo WT/ . An interesting finding in this study is that the severe reduction of sEPO in the adult leads to a moderate rather than a severe anemia. In this respect it is important to recognize that some residual Epo mRNA and sEPO remained in the Epo / mice even after 20 days of continuous induction. Cre expression in these mice was driven by the ubiquitously expressed Rosa26 locus; however, expression of this locus is variable between tissues (Zambrowicz et al., 1997) . Therefore, it is possible that a number of peritubular cells within the kidney escape Cre activity, leading to the residual EPO production. Alternatively, EPO production in secondary tissues such as liver or lung could contribute to the observed residual EPO. However, several previous observations argue against this view. First, EPO from secondary tissues only accounts for a small percentage of the total circulating EPO (Fried et al., 1969) . Second, liver and lung tissues have been shown to express the highest levels of the CRE-ERT2 transgene and therefore excision of the Epo allele in these tissues is likely to be of a high degree (Jullien et al., 2008) . Finally, in preliminary experiments we attempted to quantify hepatic Epo mRNA levels in Epo / mice as well as control animals but were not able to detect significant levels (data not shown). Because the renal Epo mRNA expression and sEPO levels measured in the whole blood serum are in tight agreement, it seems unlikely that EPO derived from different Crenegative tissues is responsible for the prevention of a severe anemia. Furthermore, Epo / mice have a tenfold reduction of Bcl2l, a well-characterized downstream mediator of EPO activity, in the bone marrow (Dolznig et al., 2002) . Taken together, these data show that the induction of Cre activity leads to a significant but incomplete loss of Epo expression throughout the adult animal in this model. The commonly used preclinical anemia models are not suited to study the anemia of EPO deficiency, owing to the normal state of the Epo response in these animals. However, several transgenic approaches have been undertaken to overcome this hurdle. In an attempt to characterize Epo-expressing cells in vivo, Maxwell and colleagues established a transgenic mouse model in which the SV40-TAg sequence was inserted into the 5Ј end of the Epo gene (EPO-TAg) (Maxwell et al., 1993) . Mice homozygous for this allele develop a severe chronic anemia with sEPO levels below the detection limit. By contrast, the Epo / mice described here displayed a mild-to-moderate chronic anemia with measurable sEPO levels, albeit much lower than expected for the HCT observed. In this respect it is important to note that a major difference between the EPO-TAg mice and the animals described here is the nature of the Epo gene modification. Whereas the Epo / mice are obtained via induced Cre-mediated excision, the EPO-TAg mice are derived from breeding carriers of the modified allele so that all cells in the animal carry the modified Epo allele. By contrast, the less severe loss of sEPO levels in the Epo / mice is probably the result of incomplete deletion of the Epo allele. Thus, the Epo / mice exhibit a phenotype that is more closely related to the clinical display of anemia in CKD. Furthermore, EPO-TAg mice develop an immune response to EPO, probably owing to a sensitizing effect of the expressed SV40 T antigen (Rinsch et al., 2002) . Thus, the EPO-TAg mice represent a critical EPO-deficient anemia, whereas the anemia observed in Epo / mice seems to be more closely related to the clinical presentation of anemia in CKD patients. In another model, Gruber and colleagues reported that the inducible deletion of the Hif2 transcription factor in the adult animal results in an anemia that is similar to the one described here for the Epo / model (Gruber et al., 2007) . However, the observed sEPO levels in these animals are significantly higher than those observed in Epo / mice and therefore are not representative of an EPO-deficiency anemia. Because HIF transcription factors are known to regulate several genes, it can be suspected that the anemia observed in these animals is multifactorial and not exclusively based on EPO deficiency (Mastrogiannaki et al., 2009; Rankin et al., 2007; Sathyanarayana et al., 2008) . A surprising discovery of this study is that Epo / mice recover at a normal rate from an induced acute hypoxic stimulus. Whereas, overall, Epo / mice display lower HCT and sEPO levels, the recovery rate of these animals is similar to their wild-type counterparts. The low levels of sEPO measured in Epo / mice cannot account for the normal recovery to the hypoxic stress because injections of a low EPO dose had no effect on erythropoietic output. Further studies are needed to determine whether, under severe hypoxic conditions, erythroid precursors dislodge from the bone marrow in the Epo / mice and populate the spleen or whether expansion of splenic precursors alone is sufficient to account for the observed normal response. Another possible explanation for the observed normal recovery rate is that erythroblasts in the Epo / mice become hypersensitive to EPO (Perry et al., 2007) . However, injecting low concentrations of rHuEPO, comparable to the sEPO levels observed in Epo / mice under anemic conditions, are in contrast with this hypothesis because we did not observe an increase in erythropoiesis.
In this study we demonstrate that the anemia of Epo / mice is similar to the clinical presentation of anemia in CKD patients (Artunc and Risler, 2007) . These patients suffer from a loss of kidney function and develop a severe anemia from the lack of EPO production (van der Putten et al., 2008) . Thus, these patients display a low HCT in conjunction with low sEPO levels, similar to the observation in Epo / mice (Artunc and Risler, 2007) . In addition, CKD patients are able to maintain low sEPO levels and are therefore not completely deprived of EPO, similar to the model described here. It should be noted that patients with CKD display normal hepatic EPO production, in contrast to the model described here. In Epo / mice, the Epo gene is excised ubiquitously and
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Preclinical model for anemia of CKD contributing to the anemia in these patients. Because CKD patients experience a significant amount of inflammation, it is possible that factors that oppose erythropoiesis are increased in these patients. In this respect it is of interest that it has been shown that the iron regulator hepcidin can suppress CFU-E development and levels of hepcidin are increased in CKD patients (Ashby et al., 2009; Tomosugi et al., 2006) . Therefore, the anemia of CKD seems to be multifactorial rather than an anemia of EPO deficiency alone. The Epo / mice described here will offer a preclinical model to study the biology of the anemia of CKD. For example, treating these animals with hepcidin might help to dissect the role of this regulator in the anemia of CKD. In summary, our data show that the conditional deletion of Epo in the adult animal results in an anemia of EPO deficiency. We did not observe any changes in the behavior, body weight or activity level of the animal during the time observed (>50 weeks post induction), and therefore the development of a chronic moderate anemia seems to be well tolerated by the animals. Also, these transgenic animals have the ability to survive for long term studies, unlike previously used models such as those using nephrectomy. Thus, Epo / mice will be a valuable tool for the development of new therapeutic approaches for the treatment of the anemia of CKD. In addition, this model will allow the study of erythropoiesis under EPO-limiting conditions as well as studies analyzing the contribution of extra-renal EPO production to erythropoiesis. Furthermore, analyzing the stress-induced erythropoietic response in these animals has the potential to discover new erythropoiesisregulating mechanisms that are masked by EPO in the currently used models. Elucidating these mechanisms has the potential to identify new target opportunities for the treatment of anemia. Finally, these animals will allow the study of the effects of EPO outside the erythropoietic system. For example, EPO has been shown to ameliorate overall cardioprotective activity and the Epo / mice could provide a valuable model to study these effects in detail.
METHODS
Generation of Epo conditional-knockout mice
A 10-kb targeting vector encompassing all five Epo exons and flanking genomic regions was created using recombinogenic engineering technology (Liu et al., 2003) . A loxP site was inserted into intron 1 followed by a neomycin-resistance cassette and a second loxP site inserted into intron 4. The targeting vector was linearized by NotI restriction-enzyme digestion and electroporated into the Bruce4 embryonic stem cell line (Lakso et al., 1996) . Clones correctly targeted at both homology arms were identified by Southern blot and injected into blastocysts to generate chimeras. (Seibler et al., 2003) . Tamoxifen was administered via subcutaneous pellet (from Innovated Research of America, Sarasota, FL) implant and released at a rate of 1 mg/day for 20 days (Claxton et al., 2008) . To induce an acute stress response, PHZ (Sigma-Aldrich, St Louis, MO) was intraperitonally injected at a concentration of 40 mg/kg (Agosti et al., 2009; Nakano et al., 2005) . To rescue transgenic mice, rHuEPO (Amgen, Seattle, WA) was diluted in PBS and injected at 120 U/kg (for low-dose experiments) and 1200 U/kg (for high-dose experiments) in 500 l per mouse subcutaneously (Albertengo et al., 1999) . 4 days later, mouse whole blood was collected via heart stick and analyzed by CBC and flow cytometric analysis. The animal care and use program is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.
The mice used in the study were generated by Pfizer's Genetically Modified Mice department and are available to the scientific community. To obtain these mice please contact the senior author of this manuscript.
qRT-PCR
Kidney and heart tissues were extracted then flash frozen and ground down to a powder with a mortar and pestle. Total RNA was extracted using RNeasy Mini Kit from Qiagen (Valencia, CA). First-strand cDNA was generated using reverse transcriptase SuperscriptIII and oligo (dT) 20 primers. Real-time PCR was performed in duplicate on an Applied Biosystems (Carlsbad, CA) HT-7900 7900 Real-Time PCR.
The following primers were used for SYBR-Green detection: Epo forward: 5Ј-AGGAGGCAGAAAATGTCACG-3Ј, Epo reverse: 5Ј-GGCCTTGCCAAACTTCTATG-3Ј; Cyclophilin forward: 5Ј-AGAGAAATTTGAGGATGAGAACTTCA-3Ј, Cyclophilin reverse:
5Ј-TTGTGTTTGGTCCAGCATTTG-3. Absolute quantification of each gene was calculated by the standard curve method using ten-fold dilutions of a positive control (PHZ treated, Epo WT/WT kidney cDNA). Bcl2l1 primers were acquired from Qiagen, Unigene number, Mm.238213. Expression of individual genes was normalized to cyclophilin expression.
Cellular analysis
For flow cytometric analysis, bone marrow and spleen samples were passed through a 40-m nylon mesh filter to create a single-cell suspension. 2ϫ10 6 cells/ml were treated with 1 L Fc blocking antibody (2.4G2) for 20 minutes at 4°C then incubated with anti-CD71-FITC (C2) and anti-Ter-119-APC (BD/Pharmingen, San Jose, CA) for 45 minutes at 4°C in the dark. Samples were washed with PBS and suspended in 200 l FACS buffer. Isotype controls were APC-Rat IgG2b and FITC-Rat IgG 1  for Ter119 and CD71, respectively, from BD/Pharmingen. Cells were processed on a BD Caliber flow cytometer and the raw data analyzed using FlowJo software (Tree Star, Portland, OR).
Mouse whole blood was analyzed using a CELL-DYN 3700 (Abbott Laboratories). The remaining blood was spun and serum collected for ELISA analysis. sEPO levels were detected by mouse ELISA hypoxia kit (Meso-Scale Discovery, Gaithersburg, MD) and evaluated using a MSD Sector Imager 6000. For whole blood reticulocytes measurement, cells were stained with thiazole orange from Sigma-Aldrich for 30 minutes at room temperature in the dark and the fluorescence intensity was measured (Maltby et al., 2009) .
For colony-forming assay (StemCell Technologies, Vancouver, BC) were performed as previously described (Zeigler et al., 2006) . Bone marrow cells were plated at a density of 1ϫ10 4 cells in 4 ml of MethoCult per 35-mm dish and spleen cells were plated 1ϫ10 5 cells per dish. The number of CFU-Es was determined 2 days after culture and BFU-Es were counted on day 4.
Preclinical model for anemia of CKD
RESEARCH ARTICLE TRANSLATIONAL IMPACT Clinical issue
Anemia characterized by low erythrocyte counts and reduced serum erythropoietin (sEPO) is commonly observed in patients with chronic kidney disease (CKD). Anemia decreases the capacity of the blood to efficiently oxygenate the tissues of the body and therefore decreases the patient's quality of life. Although recombinant human EPO is an approved treatment, this biologic is not effective in certain subsets of CKD patients and also has potential adverse effects. Therefore, the development of erythropoiesisstimulating agents would offer valuable alternative treatment options. However, there has been a lack of experimental models that accurately represent the EPO-deficiency anemia seen in CKD patients and in which new therapies can be tested.
Results
Deletion of the Epo gene in mice causes embryonic lethality; therefore, to create a new model of EPO-deficient anemia, the authors of this study develop an Epo conditional-knockout mouse by inserting loxP sites into the Epo gene. By crossing mice carrying this floxed Epo allele with mice carrying an inducible Cre transgene, Epo is postnatally ablated. When Cre activity is induced in the new strain, Epo expression is substantially reduced. These mice develop a chronic, normocytic and normochromic anemia, and display low sEPO levels, a phenotype that resembles the clinical symptoms of patients that suffer from anemia caused by CKD. Surprisingly, although Epo conditional-knockout mice display lower hematocrit and reduced sEPO levels compared with wild-type mice, their rate of recovery following an induced acute hypoxic stimulus is similar. This suggests that there are other pathways that can compensate for the loss of EPO during hypoxic stress.
Implications and future directions
The Epo conditional-knockout mouse model will provide a tool for preclinical studies of EPO-deficiency anemia caused by CKD. In addition, because these animals do not develop the inflammation or uremia observed in CKD patients, this model will allow the study of erythropoiesis in an EPO-limiting environment in the absence of secondary complications. Furthermore, analyzing responses of these mice to hypoxic stress has the potential to uncover new erythropoiesis-regulating mechanisms that are masked by EPO in currently used models of anemia. Finally, this model will allow investigation of potential roles of EPO outside the erythropoietic system. doi:10.1242/dmm.006718
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